Canaccord Genuity cuts HEALTH CATALYST INC target price to 9 dollars

Summary

Canaccord Genuity has lowered its target price for Health Catalyst Inc from $10 to $9.Reuters

Impact Analysis

This event is classified at the company level, focusing on Health Catalyst Inc. Canaccord Genuity’s decision to lower the target price could indicate a bearish outlook or perceived risk factors that might affect the company’s stock. Despite Health Catalyst’s first-quarter revenue growth of 6.3% and strong financial performance Yahoo Finance, Reuters, the reduction in target price suggests caution, possibly due to the decline in adjusted earnings per share from 5 cents to 1 cent Reuters. Market perception may be influenced, leading to potential volatility in stock price. Opportunities for investors may arise if the market overreacts negatively, creating potential buy-in points. Risks include continued pressure on earnings per share and investor confidence challenges.